These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 30796196)

  • 21. BCL2L1 inhibitor A-1331852 inhibits MCL1 transcription and triggers apoptosis in acute myeloid leukemia cells.
    Chiou JT; Wu YY; Lee YC; Chang LS
    Biochem Pharmacol; 2023 Sep; 215():115738. PubMed ID: 37562509
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using CETSA assay and a mathematical model to reveal dual Bcl-2/Mcl-1 inhibition and on-target mechanism for ABT-199 and S1.
    Guo Z; Song T; Xue Z; Liu P; Zhang M; Zhang X; Zhang Z
    Eur J Pharm Sci; 2020 Jan; 142():105105. PubMed ID: 31669390
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
    Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
    J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual targeting of MCL1 and NOXA as effective strategy for treatment of mantle cell lymphoma.
    Höring E; Montraveta A; Heine S; Kleih M; Schaaf L; Vöhringer MC; Esteve-Arenys A; Roué G; Colomer D; Campo E; Ott G; Aulitzky WE; van der Kuip H
    Br J Haematol; 2017 May; 177(4):557-561. PubMed ID: 28295185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexes.
    Seiller C; Maiga S; Touzeau C; Bellanger C; Kervoëlen C; Descamps G; Maillet L; Moreau P; Pellat-Deceunynck C; Gomez-Bougie P; Amiot M
    Cell Death Dis; 2020 May; 11(5):316. PubMed ID: 32371863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCL2 and MCL1 inhibitors for hematologic malignancies.
    Roberts AW; Wei AH; Huang DCS
    Blood; 2021 Sep; 138(13):1120-1136. PubMed ID: 34320168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MLN4924 induces Noxa upregulation in acute myelogenous leukemia and synergizes with Bcl-2 inhibitors.
    Knorr KL; Schneider PA; Meng XW; Dai H; Smith BD; Hess AD; Karp JE; Kaufmann SH
    Cell Death Differ; 2015 Dec; 22(12):2133-42. PubMed ID: 26045051
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tyrosine Kinase Inhibitors Increase MCL1 Degradation and in Combination with BCLXL/BCL2 Inhibitors Drive Prostate Cancer Apoptosis.
    Arai S; Jonas O; Whitman MA; Corey E; Balk SP; Chen S
    Clin Cancer Res; 2018 Nov; 24(21):5458-5470. PubMed ID: 30021909
    [No Abstract]   [Full Text] [Related]  

  • 30. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1.
    Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z
    Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BH3 Inhibitor Sensitivity and Bcl-2 Dependence in Primary Acute Lymphoblastic Leukemia Cells.
    Alford SE; Kothari A; Loeff FC; Eichhorn JM; Sakurikar N; Goselink HM; Saylors RL; Jedema I; Falkenburg JH; Chambers TC
    Cancer Res; 2015 Apr; 75(7):1366-75. PubMed ID: 25649768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The anti-apoptotic protein BCL2L1/Bcl-xL is neutralized by pro-apoptotic PMAIP1/Noxa in neuroblastoma, thereby determining bortezomib sensitivity independent of prosurvival MCL1 expression.
    Hagenbuchner J; Ausserlechner MJ; Porto V; David R; Meister B; Bodner M; Villunger A; Geiger K; Obexer P
    J Biol Chem; 2010 Mar; 285(10):6904-12. PubMed ID: 20051518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines.
    Merino D; Kelly GL; Lessene G; Wei AH; Roberts AW; Strasser A
    Cancer Cell; 2018 Dec; 34(6):879-891. PubMed ID: 30537511
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia.
    Besbes S; Pocard M; Mirshahi M; Billard C
    Crit Rev Oncol Hematol; 2016 Apr; 100():32-6. PubMed ID: 26899021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BCL-2 selective inhibitor ABT-199 primes rhabdomyosarcoma cells to histone deacetylase inhibitor-induced apoptosis.
    Heinicke U; Haydn T; Kehr S; Vogler M; Fulda S
    Oncogene; 2018 Sep; 37(39):5325-5339. PubMed ID: 29858601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Co-targeting bromodomain and extra-terminal proteins and MCL1 induces synergistic cell death in melanoma.
    Tseng HY; Dreyer J; Emran AA; Gunatilake D; Pirozyan M; Cullinane C; Dutton-Regester K; Rizos H; Hayward NK; McArthur G; Hersey P; Tiffen J; Gallagher S
    Int J Cancer; 2020 Oct; 147(8):2176-2189. PubMed ID: 32249419
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gossypol increases expression of the pro-apoptotic BH3-only protein NOXA through a novel mechanism involving phospholipase A2, cytoplasmic calcium, and endoplasmic reticulum stress.
    Soderquist RS; Danilov AV; Eastman A
    J Biol Chem; 2014 Jun; 289(23):16190-9. PubMed ID: 24778183
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.
    Rahmani M; Nkwocha J; Hawkins E; Pei X; Parker RE; Kmieciak M; Leverson JD; Sampath D; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2018 Jun; 78(11):3075-3086. PubMed ID: 29559471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemia.
    Iacovelli S; Ricciardi MR; Allegretti M; Mirabilii S; Licchetta R; Bergamo P; Rinaldo C; Zeuner A; Foà R; Milella M; McCubrey JA; Martelli AM; Tafuri A
    Oncotarget; 2015 Oct; 6(31):32089-103. PubMed ID: 26392332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with
    Uchida A; Isobe Y; Asano J; Uemura Y; Hoshikawa M; Takagi M; Miura I
    Haematologica; 2019 Jul; 104(7):1417-1421. PubMed ID: 30523053
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.